Clinical Trials

36 enrolled

Phase 1 Not yet recruiting

Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT07444710 2026-04-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

16 enrolled

Phase 3 Not yet recruiting

Ann Arbor Stage II Mantle Cell Lymphoma

NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

342 enrolled

Rhabdomyosarcoma

NCT07444918 2026-03-03

Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors

33 enrolled

Phase 1/2 Not yet recruiting

Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT07387926 2026-02-04

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

50 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07321912 2026-01-08

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

406 enrolled

Phase 2/3 Not yet recruiting

Sarcoma, Ewing, Osteosarcoma

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

1,708 enrolled

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

23 enrolled

Phase 1 Not yet recruiting

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07278856 2025-12-12

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

20 enrolled

Lymphoma, T-Cell

NCT07227584 2025-11-12

ALL Backbone in AYAs

67 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07092306 2025-07-29

A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma

74 enrolled

Sarcoma, Ewing

NCT06921044 2025-04-10

A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL

33 enrolled

Phase 1 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06710821 2024-11-29

Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors

40 enrolled

Other solid neoplasm

Solid Tumor Cancer

NCT06701344 2024-11-22

GOAL

7 enrolled

Enteropathy-Associated T-Cell Lymphoma

NCT06516978 2024-07-24

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

528 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06175702 2023-12-19

LALPh2022

Not yet recruiting

150 enrolled

Phase NA Not yet recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05990985 2023-08-18

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

20 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

100 enrolled